Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Thomas Hong – Manager-Investor Communications Jacque Shea – President and Chief Executive Officer Michael Sumner – Chief Medical Officer Peter Kies – Chief Financial Officer Conference Call Participants Hartaj Singh – Oppenheimer & Company Operator Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. [Operator instructions] Please note that this event is being ...

Corporate Presentation November 2022 :INO Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements,"" within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Jacqueline Shea - President and CEO Conference Call Participants Brooke Katsof - H.C. Wainwright Brooke Katsof Good morning, everyone and thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference from September 12 to the 14, 2022. My name is Brooke Katsof and I'm an H.C. Wainwright analyst. While we are hybrid this year, we're c ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Thomas Hong - IR Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer David Liebowitz - SVP, Clinical Development Jeffrey Skolnik - SVP, Clinical Development Peter Kies - CFO Conference Call Participants Alexandria Hammond - Bank of America Merrill Lynch Gregory Renza - RBC Capital Markets Jiale Song - Jefferies Eka Gigauri - Oppenheimer Raghuram Selvaraju - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q COMMISSION FILE NO. 001-14888 https://files.reportify.cc/media/p INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 660 W. GERMANTOWN PIKE, SUITE 110 PLYMOUTH MEETING, PA 19462 (Address of principal executive offices) REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (267) 4 ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Jefferies 2022 Global Healthcare Conference June 8, 2022 1:00 PM ET Company Participants Jacqui Shea - CEO Jeffrey Skolnik - CMO Conference Call Participants Roger Song - Jefferies Roger Song Good afternoon, everyone. Welcome to Jefferies Global Healthcare Conference day one afternoon. My name is Roger Song, one of the senior analysts on the biotech research team in the US. Our next presenting company from -- is Inovio and the presenter is the CEO, Jacqui and CMO, J ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of ...

Powering a New Decade of DNA Medicines March 2022 :INO Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements,"" within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-lookin ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2021 Results Conference Call March 1, 2022 4:30 PM ET Company Participants Ben Matone - Senior Director, IR Dr. Joseph Kim - President and CEO Peter Kies - CFO Dr. Jeffrey Skolnik - SVP, Clinical Development Dr. Kate Broderick - SVP, Research and Development Conference Call Participants Hartaj Singh - Oppenheimer Stephen Willey - Stifel Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon and welcome to the Inovio Pharmaceuticals Fourth Quarte ...